{"product_id":"buy-hgh-fragment-176-191-canada","title":"HGH Fragment (176-191)","description":"\u003ch2\u003e\u003cb\u003eBuy HGH Fragment 176-191 Canada — Lipolytic hGH Peptide\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eHGH Fragment 176-191 is a synthetic 16-amino-acid peptide corresponding to the C-terminal region of human growth hormone (residues 176-191), engineered to isolate the lipolytic activity of hGH from its broader endocrine effects. Canadian research labs looking to buy HGH Fragment 176-191 (also known as AOD-9604 in clinical-development contexts) source the compound for laboratory work in adipose-specific lipolysis research independent of the GH\/IGF-1 axis.\u003c\/p\u003e\n\u003cp\u003eMechanistically, the fragment retains the lipolytic and anti-lipogenic activity of full-length hGH while lacking the residues required for IGF-1 stimulation and broader growth-axis signaling. Published preclinical work has characterized its activity as targeting adipocyte β3-adrenergic-like signaling, with downstream effects on hormone-sensitive lipase activation, fatty acid oxidation, and triglyceride mobilization in adipose tissue.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eProduct Details\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eForm:\u003c\/b\u003e Lyophilized peptide\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eNet per vial:\u003c\/b\u003e 10 mg (filled to approximately 104% of label)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003ePurity:\u003c\/b\u003e ≥99% (HPLC-verified)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eIdentity:\u003c\/b\u003e MS-verified (per COA)\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eStorage:\u003c\/b\u003e 2–8 °C, protect from light\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eFormula \/ M.W.:\u003c\/b\u003e C₇₈H₁₂₅N₂₃O₂₃S₂ \/ 1817.12 Da\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCAS:\u003c\/b\u003e 221231-10-3\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eWhat Makes HGH Fragment 176-191 a Unique Compound\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eHGH Fragment 176-191 was developed in the late 1990s by Frank Ng and colleagues at Monash University, Australia, as part of a structure-activity program designed to isolate the lipolytic domain of human growth hormone from its broader endocrine activity. The compound was subsequently licensed to Metabolic Pharmaceuticals — later Calzada — and advanced through Phase 2 clinical trials in obesity in the early 2000s under the development code AOD-9604.\u003c\/p\u003e\n\u003cp\u003eWhat distinguishes the fragment in research is its mechanistic specificity. Full-length hGH binds the GH receptor and triggers the complete cascade — IGF-1 elevation, growth signaling, glucose handling, and lipolysis. By using only the C-terminal 16 residues, HGH Fragment 176-191 retains lipolytic activity without engaging the GH receptor in the IGF-1-stimulating mode. That decoupling gives Canadian research groups a clean tool for studying adipose-specific hGH actions in isolation from the systemic GH\/IGF-1 axis effects that confound full-hGH study designs.\u003c\/p\u003e\n\u003ch2\u003e\u003cb\u003eKey Benefits\u003c\/b\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003eLipolysis \u0026amp; Fatty Acid Mobilization —\u003c\/b\u003e Published preclinical studies have characterized HGH Fragment 176-191's activation of hormone-sensitive lipase and stimulation of fatty acid release from adipose tissue, with effects observed in both subcutaneous and visceral adipocyte models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eAnti-Lipogenic Activity —\u003c\/b\u003e Animal studies have measured reductions in fatty acid synthesis alongside increased lipolysis, generating sustained interest in the fragment as a research tool for adipose-specific dual-mechanism investigation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eBody Composition Models —\u003c\/b\u003e Rodent obesity models have reported reductions in fat mass without proportional changes in lean mass following HGH Fragment 176-191 administration, with mechanistic work attributing the selectivity to the absence of GH-receptor-mediated growth signaling.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eDecoupled Metabolic Research —\u003c\/b\u003e Unlike full hGH, the fragment does not substantially elevate IGF-1 or alter glucose homeostasis in published animal models, making it a useful tool for research designs requiring lipolysis activity without confounding GH\/IGF-1 axis effects.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003eCartilage \u0026amp; Joint Research —\u003c\/b\u003e A subset of preclinical work has examined HGH Fragment 176-191 in osteoarthritis and cartilage degradation models, characterizing effects on chondrocyte signaling that are mechanistically distinct from its primary lipolytic profile.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eRelated Peptides\u003c\/b\u003e\u003c\/h2\u003e\n\u003cp\u003eResearchers working with HGH Fragment 176-191 often investigate it alongside:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-tesamorelin-canada\" title=\"View Tesamorelin Product Page\"\u003eTesamorelin\u003c\/a\u003e\u003c\/b\u003e — GHRH analog that stimulates pituitary GH release and triggers the full GH\/IGF-1 cascade; the standard mechanistic contrast for research designs comparing isolated lipolytic activity against full-axis activation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-retatrutide-canada\" title=\"View Retatrutide Product Page\"\u003eRetatrutide\u003c\/a\u003e\u003c\/b\u003e — Triple GLP-1\/GIP\/glucagon agonist with documented adiposity-research data; provides a receptor-level metabolic-pathway contrast to HGH Fragment 176-191's adipocyte-direct lipolytic mechanism.\u003c\/li\u003e\n\u003cli\u003e\n\u003cb\u003e\u003ca href=\"https:\/\/emeraldpeptides.ca\/products\/buy-mots-c-canada\" title=\"View MOTS-c Product Page\"\u003eMOTS-c\u003c\/a\u003e\u003c\/b\u003e — Mitochondria-derived peptide that activates AMPK; complements HGH Fragment 176-191's lipolytic profile with a cellular-energetics angle on metabolic research.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cb\u003eFrequently Asked Questions\u003c\/b\u003e\u003c\/h2\u003e\n\u003ch3\u003e\u003cb\u003eWhere can researchers buy HGH Fragment 176-191 in Canada with verified purity?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eOur HGH Fragment 176-191 ships to Canadian research labs and independent investigators with a batch-specific certificate of analysis confirming ≥99% HPLC purity and mass-spec identity verification. Vials are filled to approximately 104% of the labeled 10 mg as a quality margin for residual losses during reconstitution work, and ship from within Canada to avoid border-related cold-chain interruptions.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eHow is HGH Fragment 176-191 different from Tesamorelin or full hGH?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThe three operate at different points in the GH axis. Full hGH binds the GH receptor and triggers the complete cascade — IGF-1 production, growth signaling, glucose modulation, and lipolysis. Tesamorelin is a GHRH analog that stimulates pituitary GH release, indirectly producing the full hGH cascade. HGH Fragment 176-191 isolates only the C-terminal lipolytic region of hGH, retaining fat-mobilization activity without engaging the GH receptor in the IGF-1-stimulating mode. Research designs select among the three based on whether full-axis activation, indirect GH stimulation, or isolated lipolysis is the relevant mechanism.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs HGH Fragment 176-191 the same as AOD-9604?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003eThe two are closely related and frequently treated as synonymous in research peptide markets. HGH Fragment 176-191 refers to the synthetic 16-amino-acid sequence corresponding to residues 176-191 of human growth hormone. AOD-9604 is the same fragment as developed by Metabolic Pharmaceuticals and tested in Phase 2 clinical trials in obesity. Most research suppliers use the names interchangeably, and the published preclinical literature largely treats them as equivalent compounds.\u003c\/p\u003e\n\u003ch3\u003e\u003cb\u003eIs HGH Fragment 176-191 naturally occurring?\u003c\/b\u003e\u003c\/h3\u003e\n\u003cp\u003ePartially. The 16-amino-acid sequence corresponds exactly to residues 176-191 of native human growth hormone, an endogenous peptide hormone produced by the anterior pituitary. The fragment itself does not occur freely in nature — it is a synthetic peptide isolated from the parent hGH sequence to study the lipolytic activity of that specific region. The synthetic peptide sold for research is sequence-identical to the corresponding region of native hGH.\u003c\/p\u003e\n\u003chr\u003e\n\u003cp\u003e⚠️ \u003cem\u003eFor research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.\u003c\/em\u003e\u003c\/p\u003e","brand":"Emerald Peptides","offers":[{"title":"10mg","offer_id":46398509187209,"sku":null,"price":99.99,"currency_code":"CAD","in_stock":true},{"title":"6 x 10mg","offer_id":46398509219977,"sku":null,"price":529.99,"currency_code":"CAD","in_stock":true},{"title":"10 x 10mg (one box)","offer_id":46398509252745,"sku":null,"price":829.99,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0760\/3424\/4745\/files\/HGH-peptides-canada_35c07665-3aad-4426-b8fb-58e6a6ad45ba.png?v=1778370270","url":"https:\/\/emeraldpeptides.ca\/products\/buy-hgh-fragment-176-191-canada","provider":"Emerald Peptides","version":"1.0","type":"link"}